Parkman Healthcare Partners LLC Buys Shares of 202,907 ANI Pharmaceuticals, Inc. $ANIP

Parkman Healthcare Partners LLC purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 202,907 shares of the specialty pharmaceutical company’s stock, valued at approximately $16,797,000. ANI Pharmaceuticals comprises approximately 1.7% of Parkman Healthcare Partners LLC’s investment portfolio, making the stock its 23rd largest holding. Parkman Healthcare Partners LLC owned approximately 0.89% of ANI Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ANIP. Arrowstreet Capital Limited Partnership acquired a new stake in ANI Pharmaceuticals in the third quarter valued at about $32,992,000. Ranger Investment Management L.P. bought a new position in ANI Pharmaceuticals in the second quarter valued at about $28,406,000. Deutsche Bank AG acquired a new position in ANI Pharmaceuticals during the second quarter worth about $26,775,000. Balyasny Asset Management L.P. raised its stake in ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock worth $26,211,000 after acquiring an additional 276,233 shares in the last quarter. Finally, William Blair Investment Management LLC acquired a new position in ANI Pharmaceuticals during the second quarter worth about $21,372,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, VP Meredith Cook sold 500 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $75.48, for a total transaction of $37,740.00. Following the transaction, the vice president directly owned 74,424 shares in the company, valued at approximately $5,617,523.52. This trade represents a 0.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas Haughey sold 2,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the transaction, the director directly owned 38,878 shares in the company, valued at approximately $3,144,452.64. This represents a 4.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,987 shares of company stock valued at $1,546,405 over the last three months. Corporate insiders own 8.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ANIP shares. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Canaccord Genuity Group lowered their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Finally, Guggenheim decreased their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $105.83.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $74.17 on Tuesday. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of 15.98 and a beta of 0.44. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a twelve month low of $70.15 and a twelve month high of $99.50. The stock has a fifty day simple moving average of $80.19 and a 200 day simple moving average of $78.84.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business’s quarterly revenue was up 25.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.